MedDataX Logo

Real-World Study of DLBCL With Different Genetic Subtypes

NCT ID: NCT06026488

Last Updated: 2024-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

10000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-01

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To collect and evaluate the data of real-world treatment regimen, efficacy, safety and survival information of DLBCL patients with different genetic suptypes

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

DLBCL is a highly common malignant tumor in Asia. The aim of the study is to observe and explore the clinical information on DLBCL patients with different genetic subtypes and to analyze the clinical characteristics and prognosis of different molecular subtypes of DLBCL. This study is a non-interventional real world, observational study and all registered data are collected from real clinical practice cases. The medical data includes patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, efficacy results and possible prognostic factors. The results can guide future precision therapy for DLBCL.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

DLBCL - Diffuse Large B Cell Lymphoma Lymphoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

lymphoma DLBCL Genetic Subtype real world analysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All enrolled patients

All patient who signed the consent form for participation to the study

Other

Intervention Type OTHER

real world treatment and survival of DLBCL patients in China

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Other

real world treatment and survival of DLBCL patients in China

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically-confirmed diffuse large B-cell lymphoma (DLBCL)
* Genetic subtype belonging to at least one of the seven subtypes by using next generation sequencing: MCD, BN2, N1, ST2, A53, EZB (MYC+, MYC-) and others
* Fully comprehension and signature of the informed consent form (ICF) for participation

Exclusion Criteria

* Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period
* Severe mental illness
* Patients deemed unsuitable for inclusion by the investigator
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ruijin Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zhao Weili

Principal Investigator, Clinical Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Weili Zhao

Role: CONTACT

Phone: +862164370045

Email: [email protected]

Pengpeng Xu

Role: CONTACT

Phone: +862164370045

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Weili Zhao, MD, PhD

Role: primary

Pengpeng Xu, MD, PhD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DLBCL-RWS-01

Identifier Type: -

Identifier Source: org_study_id